Table 3.
Molecular characteristics of cancers from the retrospective studies. The third and fourth columns provide information on the total number of patients and number of series that had data for each biomarker.
| Patients (%) | Total Patients with Data | Number of Series with Data | |
|---|---|---|---|
| MSI | |||
| pMMR/MSS | 98 (81.7%) | 120 | 3 |
| dMMR/MSI | 3 (2.5%) | ||
| Unknown | 19 (15.8%) | ||
| KRAS MUTATION STATUS | |||
| Wild-type | 207 (46.9%) | 441 | 8 |
| Mutated | 228 (51.7%) | ||
| Unknown | 6 (1.4%) | ||
| NRAS MUTATION STATUS | |||
| Wild-type | 44 (81.5%) | 54 | 1 |
| Mutated | 4 (7.4%) | ||
| Unknown | 6 (11.1%) | ||
| BRAF MUTATION STATUS | |||
| Wild-type | 240 (92.7%) | 259 | 4 |
| Mutated | 9 (3.5%) | ||
| Unknown | 10 (3.8%) |